Skin, Soft Tissue, and Bone Infections Due to Mycobacterium chelonae chelonae: Importance of Prior Corticosteroid Therapy, Frequency of Disseminated Infections, and Resistance to Oral Antimicrobials Other than Clarithromycin

Journal of Infectious Diseases

Volumn 166, Issue 2, 1992, Pages 405-412

  Wallace, Richard J ^a   Brown, Barbara A ^a   Onyi, Grace O ^a  

^a UNIVERSITY OF TEXAS AT TYLER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; DOXYCYCLINE; ERYTHROMYCIN; OFLOXACIN; PIPEMIDIC ACID; POLYMYXIN B; SULFAMETHOXAZOLE; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BONE INFECTION; CLINICAL FEATURE; CORTICOSTEROID THERAPY; GEOGRAPHIC DISTRIBUTION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MYCOBACTERIOSIS; MYCOBACTERIUM CHELONEI; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN INFECTION; SOFT TISSUE INFECTION;

ABSCESS; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ANTI-INFECTIVE AGENTS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CATHETERS, INDWELLING; CELLULITIS; CLARITHROMYCIN; DRUG RESISTANCE, MICROBIAL; ERYTHROMYCIN; HUMAN; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM INFECTIONS, ATYPICAL; ORGAN TRANSPLANTATION; OSTEOMYELITIS; RISK FACTORS; SKIN DISEASES, INFECTIOUS; UNITED STATES;

EID: 0026770337     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/166.2.405     Document Type: Article

References (64)

1. Wallace RJ Jr. Swenson JM, Silcox VA, Good RC, Tschen JA, Stone MS. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis 1983; 5:657-79.
2. Cooper JF, Lichtenstein MJ, Graham BS, Schaffner W. Mycobacterium chelonae: a cause of nodular skin lesions with a proclivity for renal transplant recipients. Am J Med 1989; 86:173-7.
3. Lowry PW, Jarvis WR, Oberle AD, et al. Mycobacterium chelonae causing otitis media in an ear-nose-and-throat practice. N Engl J Med 1988; 319:978-82.
4. Safranek TJ, Jarvis WR, Carson LA, et al. Mycobacterium chelonae wound infections after plastic surgery employing contaminated gentian violet skin-marking solution. N Engl J Med 1987; 317:197-201.
5. Bolan G, Reingold AL, Carson LA, et al. Infections with Mycobacterium chelonei in patients receiving dialysis and using processed he-modialyzers. J Infect Dis 1985; 152:1013-9.
6. Lowry PW, Beck-Sague CM, Bland LA, et al. Mycobacterium chelonae infection among patients receiving high-flux dialysis in a hemodialysis clinic in California. J Infect Dis 1990; 161:85-90.
7. Kuritsky JN. Bullen MG, Broome CV, Silcox VA, Good RC, Wallace RJ Jr. Sternal wound infections and endocarditis due to organisms of the Mycobacterium fortuitum complex. Ann Intern Med 1983; 98:938-9.
8. Szabό I, Sárközi K. Mycobacterium chelonei endemy after heart surgery with fatal consequences. Am Rev Respir Dis 1980; 121:607.
9. Hoffman PC, Fraser DW, Robicsek F, O'Bar PR, Mauney CU. Two outbreaks of sternal wound infections due to organisms of the Mycobacterium fortuitum complex. J Infect Dis 1981; 143:533-42.
10. Wenger JD, Spika JS, Smithwick RW, et al. Outbreak of Mycobacterium chelonae infection associated with use of jet injectors. JAMA 1990; 264:373-6.
11. Gremillion DH, Mursch SB, Lerner CJ. Injection site abscesses caused by Mycobacterium chelonei. Infect Control 1983; 4:25-8.
12. Kubica GP, Baess I, Gordon RE, et al. A co-operative numerical analysis of rapidly growing mycobacteria. J Gen Microbiol 1972; 73:55-70.
13. Silcox VA. Good RC, Floyd MM. Identification of clinically significant Mycobacterium fortuitum complex isolates. J Clin Microbiol 1981; 14:686-91.
14. Wallace RJ Jr. Swenson JM, Silcox VA, Good RC. Disk diffusion testing with polymyxin and amikacin for differentiation of Mycobacterium fortuitum and Mycobacterium chelonei. J Clin Microbiol 1982; 16:1003-6.
15. Casal MJ, Rodriguez FC. Simple, new test for rapid differentiation of the Mycobacterium fortuitum complex. J Clin Microbiol 1981; 13:989-90.
16. Steele LC, Wallace RJ Jr. Ability of ciprofloxacin but not pipemidic acid to differentiate all three biovariants of Mycobacterium fortuitum from Mycobacterium chelonae. J Clin Microbiol 1987; 25:456-7.
17. Swenson JM. Wallace RJ Jr. Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985; 28:807-11.
18. Swenson JM, Thornsberry C, Silcox VA. Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution. Antimicrob Agents Chemother 1982; 22:186-92.
19. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2nd ed. Villanova, PA: NCCLS, 1991; approved standard; document M7-A2.
20. Brown BA, Wallace RJ Jr, OnyiGO, DeRosas V, Wallace RJ III. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum. Mycobacterium chelonae, and M. chelonae-Yike organisms. Antimicrob Agents Chemother 1992; 36:180-4.
21. Merlin TL, Tzamaloukas AH. Mycobacterium chelonae peritonitis associated with continuous ambulatory peritoneal dialysis. Am J Clin Pathol 1989; 91:717-20.
22. Wallace RJ Jr, Bedsole G. Sumter G, et al. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob Agents Chemother 1990; 34:65-70.
23. Wallace RJ Jr, Nash DR, Tsukamura M, Blacklock ZM, Silcox VA. Human disease due to Mycobacterium smegmatis. J Infect Dis 1988; 158:52-9.
24. Wallace RJ Jr, Brown BA, Silcox VA, et al. Clinical disease, drug susceptibility and biochemical patterns of the unnamed third biovariant complex of Mycobacterium fortuitum. J Infect Dis 1991; 163:598-603.
25. Grange JM. Mycobacterium chelonei. Tubercle 1981;62:273-6.
26. Bonicke R, Stottmeier D. Erkennung und Identifizierung der Species Mycobacterium borstelense. Beitr Klin Tuberc 1965; 130:210-22.
27. Tsukamura M. Numerical analysis of rapidly growing, nonphotochro-mogenic mycobacteria, including Mycobacterium agri (Tsukamura 1972) Tsukamura sp. nov., nom. rev. Int J Syst Bacteriol 1981; 32:247-58.
28. Stanford JL, Pattyn SR, Portaels F. Gunthorpe WJ. Studies on Mycobacterium chelonei. J Med Microbiol 1972; 5:177-82.
29. Wayne LG. Kubica GP. Mycobacteriaceae. In: Sneath HA, ed. Bergey's manual of systematic bacteriology. Vol 2. Baltimore: Williams & Wilkins, 1986:1452-3.
30. Lévy-Frebault V, Grimont F, Grimont PAD. David HL. Deoxyribonucleic acid relatedness study of the Mycobacterium fortuitum-Mycobacterium chelonae complex. Int J Syst Bacteriol 1986; 36:458-60.
31. Butler WR, Kilbum JO. High-performance liquid chromatography patterns of mycolic acids as criteria for identification of Mycobacterium chelonae. Mycobacterium fortuitum, and Mycobacterium smegmatis. J Clin Microbiol 1990;28:2094-8.
32. Graybill JR, Silva J Jr, Fraser DW, Lordon R, Rogers E. Disseminated mycobacteriosis due to Mycobacterium abcessus in two recipients of renal homografts. Am Rev Respir Dis 1974; 109:4-10.
33. Arroyo J, Medoff G. Mycobacterium chelonei infection: successful treatment based on a radiometric susceptibility test. Antimicrob Agents Chemother 1977; 11:763-4.
34. Tice AD, Solomon RJ. Disseminated Mycobacterium chelonei infection: response to sulfonamides. Am Rev Respir Dis 1979; 120:197-201.
35. Greer KE, Gross GP, Martensen SH. Sporotrichoid cutaneous infection due to Mycobacterium chelonei. Arch Dermatol 1979; 115:738-9.
36. Becker GJ, Walker RG, Dziukas U, Harvey KJ, Valentine R, Kincaid-Smith P. Renal infection with Mycobacterium chelonei. Aust NZ J Med 1980; 10:44-7.
37. Azadian BS, Beck A, Curtis JR, et al. Disseminated infection with Mycobacterium chelonei in a haemodialysis patient. Tubercle 1981; 62:281-4.
38. Pottage JC Jr, Harris AA, Trenholme GM, Levin S, Kaplan RL, Feczko JM. Disseminated Mycobacterium chelonei infection: a report of two cases. Am Rev Respir Dis 1982; 126:720-2.
39. Fojlasek MF. Kelly MT. Isolation of Mycobacterium chelonei with the lysis-centrifugation blood culture technique. J Clin Microbiol 1982; 16:403-5.
40. Hing DC, Delohery JF, Abbott MR. Multifocal osteomyelitis caused by Mycobacterium chelonei. Med J Aust 1983; 1:529-31.
41. Carpenter JL, Troxell M, Wallace RJ Jr. Disseminated disease due to Mycobacterium chelonei treated with amikacin and cefoxitin. Arch Intern Med 1984; 144:2063-5.
42. Hendrick SJ, Jorizzo JL. Newton RC. Giant Mycobacterium fortuitum abscess associated with systemic lupus erythematosus. Arch Dermatol 1986; 122:695-7.
43. Selgas R, Muñoz J, Aquella A. et al. Mycobacterium chelonei peritonitis due to hematogenous dissemination in a continuous ambulatory peritoneal dialysis patient. Am J Kidney Dis 1987; 10:144-6.
44. Murdoch ME, Leigh IM. Sporotrichoid spread of cutaneous Mycobacterium chelonei infection. Clin Exp Dermatol 1989; 14:309-12.
45. Horsburgh CR Jr. Selik RM. The epidemiology of disseminated nontu-berculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989; 139:4-7.
46. Cua EJ, Oates E. Breast uptake of gallium-67 citrate in disseminated Mycobacterium chelonei. Clin Nucl Med 1990; 15:705-6.
47. Burns DN, Rohatgi PK, Rosenthal R, Seiler M, Gordin FM. Disseminated Mycobacterium fortuitum successfully treated with combination therapy including ciprofloxacin. Am Rev Respir Dis 1990; 142:468-70.
48. Gutknecht DR. Treatment of disseminated Mycobacterium chelonae infection with ciprofloxacin. J Am Acad Dermatol 1990;23:1179-80.
49. Sack JB. Disseminated infection due to Mycobacterium fortuitum in a patient with AIDS. Rev Infect Dis 1990; 12:961-3.
50. Drabick JJ, Duffy PE, Samlaska CP, Scherbenske JM. Disseminated Mycobacterium chelonae subspecies chelonae infection with cutaneous and osseous manifestations. Arch Dermatol 1990; 126:1064-7.
51. Nelson BR, Rapini RP, Wallace RJ Jr, Tschen JA. Disseminated Mycobacterium chelonae ssp. abscessus in an immunocompetent host and with a known portal of entry. J Am Acad Dermatol 1989; 20:909-12.
52. Wallace RJ Jr, Brown BA, Onyi G. Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavu-lanic acid. Antimicrob Agents Chemother 1991; 35:773-5.
53. Johnson JS, Vaughan JH, Hcnch PK, Blomgren SE. Rheumatoid arthritis, 1970-1972. Ann Intern Med 1973; 78:937-53.
54. Huskisson EC, Hart FD. Severe, unusual, and recurrent infections in rheumatoid arthritis. Ann Rheum Dis 1972; 31:118-21.
55. Wallace RJ Jr, Steele LC, Labidi A, Silcox VA. Heterogeneity among isolates of rapidly growing mycobacteria responsible for infections following augmentation mammaplasty despite case clustering in Texas and other southern coastal states. J Infect Dis 1989; 160:281-8.
56. Wallace RJ Jr, Musser JM, Hull SI, et al. Diversity and sources of rapidly growing mycobacteria associated with infections following cardiac surgery. J Infect Dis 1989; 160:708-16.
57. Griffith DE, Garcia JGN, Wallace RJ Jr. Lung disease caused by rapidly growing mycobacteria. In: Annual meeting abstracts, American Thoracic Society. Am Rev Respir Dis 1988; 137:218.
58. Abscesses in an allergy practice due to Mycobacterium chelonae. Georgia Epidemiol Rep 1990; 6:2.
59. Epidemiologic notes and reports: follow-up on mycobacterial contamination of porcine heart valve prostheses-United States. MMWR 1978; 27:92.
60. Borghans JGA, Stanford JL. Mycobacterium chelonei in abscesses after injection of diphtheria-pertussis-tetanus-polio vaccine. Am Rev Respir Dis 1973; 107:1-8.
61. Inman PM, Beck A, Brown AE, Stanford JL. Outbreak of injection abscesses due to Mycobacterium abscessus. Arch Dermatol 1969; 100:141-7.
62. Jackson PG, Keen H, Noble CJ, Simmons NA. Injection abscesses due to Mycobacterium chelonei occurring in a diabetic patient. Tubercle 1981; 62:277-9.
63. Pattyn SR. Vandepitte J, Portaels F, De Muynck A. Cases of Mycobacterium borstelense and M. abscessus infection observed in Belgium. J Med Microbiol 1971; 4:145-9.
64. Jopp-McKay AG, Randell P. Sporotrichoid cutaneous infection due to Mycobacterium chelonei in a renal transplant patient. Aust J Dermatol 1990; 31:105-9.